Mylan, Teva Launch Generic Diovan Antihypertensive Agent
Mylan and Teva have separately announced the US launches of their respective valsartan tablets, the generic version of Novartis' antihypertensive agent, Diovan.
Mylan and Teva have separately announced the US launches of their respective valsartan tablets, the generic version of Novartis’ antihypertensive agent, Diovan.
The companies’ announcements follow the FDA’s final approval of Abbreviated New Drug Applications from both Mylan and Teva for the products, which are indicated to lower blood pressure in patients with hypertension.
Both generic versions of valsartan will be available in 40 mg, 80 mg, 160 mg, and 320 mg tablets, which had approximately $2 billion worth of sales in the United States for the 12-month period ending on September 30, 2014, according to IMS Health. Novartis’ brand name Diovan had annual sales of approximately $1.8 billion in the United States, according to IMS data through October 2014.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025